CXCL9+ACKR1+

Boyu Sun1,2, Ziyu Xun3, Zixiang Zhou3

  • 1Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 1 Shuaifuyuan, Beijing, 100730, China.

概括

免疫检查点抑制剂 (ICI) 相关心肌炎涉及淋巴细胞和亲炎性纤维细胞的增加. 这项研究揭示了驱动ICI心肌炎的独特细胞机制,确定了这种罕见但致命的疾病的潜在治疗点.